Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 1.00 |
| ▸ | SLC6A9 | P48067 | 1/20 | 1.00 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 1.00 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.47 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL30070584 | 1.00 | — | — | |
| Glycine SCHEMBL3640989 | 1.00 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL30179260 | 1.00 | — | — | |
| Glycine SCHEMBL2116443 | 1.00 | — | — | |
| Glycine SCHEMBL6163 | 1.00 | — | — | |
| Glycine SCHEMBL13169653 | 1.00 | — | — | |
| Glycine SCHEMBL6675874 | 1.00 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL93765 | 1.00 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL391786 | 1.00 | GLRA1 (1.00) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL29910347 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3797 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102722-A1 | METHODS OF TREATING A TUMOR WITH AN UNMETHYLATED MGMT PROMOTER | NEOIMMUNETECH, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| US-20240115675-A1 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND A NUCLEOTIDE VACCINE | NEOIMMUNETECH, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-20240101629-A1 | USE OF INTERLEUKIN-7 FOR THE TREATMENT OF CORONAVIRUS | NEOIMMUNETECH, INC. (US) | 2024-03-28 | — | — | US | claimed |
| US-20230398184-A1 | METHODS OF INDUCING STEM CELL MOBILIZATION | NEOIMMUNETECH, INC. (US) | 2023-12-14 | — | — | US | claimed |
| EP-4240408-A1 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF AN IL-7 PROTEIN AND A NUCLEOTIDE VACCINE | NEOIMMUNETECH, INC. (US) | 2023-09-13 | — | — | EP | claimed |
| EP-4236989-A1 | USE OF INTERLEUKIN-7 FOR THE TREATMENT OF CORONAVIRUS | NeoImmuneTech, Inc. (US) | 2023-09-06 | — | — | EP | claimed |
| EP-4232070-A1 | METHODS OF INDUCING STEM CELL MOBILIZATION | NeoImmuneTech, Inc. (US) | 2023-08-30 | — | — | EP | claimed |
| WO-2023130081-A1 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND VEGF ANTAGONIST | NEOIMMUNETECH, INC. (US) | 2023-07-06 | — | — | WO | claimed |
| US-20230057939-A1 | METHOD OF TREATING A TUMOR WITH A COMBINATION OF IL-7 PROTEIN AND A BISPECIFIC ANTIBODY | NEOIMMUNETECH, INC. (US) | 2023-02-23 | — | — | US | claimed |
| CN-111778169-B | Method for improving in vitro protein synthesis efficiency | 康码（上海）生物科技有限公司 | 2023-02-10 | — | — | CN | claimed |
| EP-1135402-A1 | ANTISENSE MODULATION OF EGR-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2000039278-A2 | PTH FUNCTIONAL DOMAIN CONJUGATE PEPTIDES, DERIVATIVES THEREOF AND NOVEL TETHERED LIGAND-RECEPTOR MOLECULES | THE GENERAL HOSPITAL CORPORATION (US) | 2000-07-06 | — | — | WO | claimed |
| WO-2000034302-A1 | ANTISENSE MODULATION OF EGR-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000011158-A1 | GENETICALLY MODIFIED AND DIABETIC NON-HUMAN ANIMAL | UNIVERSITE CATHOLIQUE DE LOUVAIN (BE) | 2000-03-02 | — | — | WO | claimed |
| US-5734016-A | GENETIC ENGINEERING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-31 | — | — | US | claimed |
| EP-0560913-A1 | BIFUNCTIONAL INHIBITORS OF THROMBIN AND PLATELET ACTIVATION | BIOGEN, INC. (US) | 1993-09-22 | — | — | EP | claimed |
| WO-1992010575-A1 | BIFUNCTIONAL INHIBITORS OF THROMBIN AND PLATELET ACTIVATION | BIOGEN, INC. (US) | 1992-06-25 | — | — | WO | claimed |
| EP-0190254-A4 | CLONED GENE AND METHOD FOR MAKING AND USING THE SAME. | GENEX CORP (US) | 1987-03-09 | — | — | EP | claimed |
| EP-0190254-A1 | CLONED GENE AND METHOD FOR MAKING AND USING THE SAME | GENEX CORPORATION (US) | 1986-08-13 | — | — | EP | claimed |
| WO-1986000528-A1 | CLONED GENE AND METHOD FOR MAKING AND USING THE SAME | GENEX CORPORATION (US) | 1986-01-30 | — | — | WO | claimed |